High frequency of microsatellite instability and its substantial co‑existence with KRAS and BRAF mutations in Vietnamese patients with colorectal cancer
- Authors:
- Ha Thi Nguyen
- Do Thanh Le
- Quan Hong Duong
- Vinay Bharadwaj Tatipamula
- Bang Van Nguyen
-
Affiliations: Institute of Research and Development, Duy Tan University, Danang 550000, Vietnam, Institute for Global Health Innovations, Duy Tan University, Danang 550000, Vietnam, Laboratory Center, Hanoi University of Public Heath, Hanoi 100000, Vietnam, Anapathology Department, Hue Central Hospital, Hue 530000, Vietnam - Published online on: November 13, 2020 https://doi.org/10.3892/ol.2020.12302
- Article Number: 41
-
Copyright: © Nguyen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Pham T, Bui L, Kim G, Hoang D, Tran T and Hoang M: Cancers in Vietnam-burden and control efforts: a narrative scoping review. Cancer Contr. 26:1073274819863802. 2019. | |
|
Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell. 61:759–767. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Vogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nat Med. 10:789–799. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Nguyen HT and Duong HQ: The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy (Review). Oncol Lett. 16:9–18. 2018.PubMed/NCBI | |
|
Brenner H, Kloor M and Pox CP: Colorectal cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Grady WM and Carethers JM: Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 135:1079–1099. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Markowitz SD and Bertagnolli MM: Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med. 361:2449–2460. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Sinicrope FA and Sargent DJ: Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res. 18:1506–1512. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Worthley DL and Leggett BA: Colorectal cancer: Molecular features and clinical opportunities. Clin Biochem Rev. 31:31–38. 2010.PubMed/NCBI | |
|
Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, et al: CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 38:787–793. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Abdel-Rahman WM and Peltomäki P: Molecular basis and diagnostics of hereditary colorectal cancers. Ann Med. 36:379–388. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Pawlik TM, Raut CP and Rodriguez-Bigas MA: Colorectal carcinogenesis: MSI-H versus MSI-L. Dis Markers. 20:199–206. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Benatti P, Gafà R, Barana D, Marino M, Scarselli A, Pedroni M, Maestri I, Guerzoni L, Roncucci L, Menigatti M, et al: Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res. 11:8332–8340. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Popat S, Hubner R and Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 23:609–618. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA, Wolff RK and Slattery ML: Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology. 129:837–845. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Sinicrope FA and Sargent DJ: Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol. 21:369–373. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Wee P and Wang Z: Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel). 9:1–45. 2017. | |
|
Fernández-Medarde A and Santos E: Ras in cancer and developmental diseases. Genes Cancer. 2:344–358. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Neumann J, Zeindl-Eberhart E, Kirchner T and Jung A: Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract. 205:858–862. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kosmidou V, Oikonomou E, Vlassi M, Avlonitis S, Katseli A, Tsipras I, Mourtzoukou D, Kontogeorgos G, Zografos G and Pintzas A: Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications. Hum Mutat. 35:329–340. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Schubbert S, Shannon K and Bollag G: Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 7:295–308. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B and Velculescu VE: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 418:9342002. View Article : Google Scholar : PubMed/NCBI | |
|
Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, Stephens P, Edkins S, Tsui WW, Chan AS, et al: Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 62:6451–6455. 2002.PubMed/NCBI | |
|
De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, et al: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol. 11:753–762. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Calistri D, Rengucci C, Seymour I, Leonardi E, Truini M, Malacarne D, Castagnola P and Giaretti W: KRAS, p53 and BRAF gene mutations and aneuploidy in sporadic colorectal cancer progression. Cell Oncol. 28:161–166. 2006.PubMed/NCBI | |
|
Cantwell-Dorris ER, O'Leary JJ and Sheils OM: BRAFV600E: Implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 10:385–394. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 26:1626–1634. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, et al: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 26:5705–5712. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Bardelli A and Siena S: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 28:1254–1261. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
van Brummelen EMJ, de Boer A, Beijnen JH and Schellens JHM: BRAF mutations as predictive biomarker for response to anti-EGFR monoclonal antibodies. Oncologist. 22:864–872. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao B, Wang L, Qiu H, Zhang M, Sun L, Peng P, Yu Q and Yuan X: Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Oncotarget. 8:3980–4000. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Borràs E, Jurado I, Hernan I, Gamundi MJ, Dias M, Martí I, Mañé B, Arcusa A, Agúndez JAG, Blanca M, et al: Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. BMC Cancer. 11:4062011. View Article : Google Scholar : PubMed/NCBI | |
|
Mohamed Suhaimi NA, Foong YM, Lee DYS, Phyo WM, Cima I, Lee EXW, Goh WL, Lim WY, Chia KS, Kong SL, et al: Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients. Mol Oncol. 9:850–860. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sclafani F, Chau I, Cunningham D, Hahne JC, Vlachogiannis G, Eltahir Z, Lampis A, Braconi C, Kalaitzaki E, De Castro DG, et al: KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. Sci Rep. 8:14452018. View Article : Google Scholar : PubMed/NCBI | |
|
Nguyen HT, Geens M, Mertzanidou A, Jacobs K, Heirman C, Breckpot K and Spits C: Gain of 20q11.21 in human embryonic stem cells improves cell survival by increased expression of Bcl-xL. Mol Hum Reprod. 20:168–177. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN and Srivastava S: A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58:5248–5257. 1998.PubMed/NCBI | |
|
Findeisen P, Kloor M, Merx S, Sutter C, Woerner SM, Dostmann N, Benner A, Dondog B, Pawlita M, Dippold W, et al: T25 repeat in the 3′ untranslated region of the CASP2 gene: A sensitive and specific marker for microsatellite instability in colorectal cancer. Cancer Res. 65:8072–8078. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Nguyen HT, Markouli C, Geens M, Barbé L, Sermon K and Spits C: Human embryonic stem cells show low-grade microsatellite instability. Mol Hum Reprod. 20:981–989. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Skotheim RI, Diep CB, Kraggerud SM, Jakobsen KS and Lothe RA: Evaluation of loss of heterozygosity/allelic imbalance scoring in tumor DNA. Cancer Genet Cytogenet. 127:64–70. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Heaphy CM, Hines WC, Butler KS, Haaland CM, Heywood G, Fischer EG, Bisoffi M and Griffith JK: Assessment of the frequency of allelic imbalance in human tissue using a multiplex polymerase chain reaction system. J Mol Diagn. 9:266–271. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Gilder JR, Inman K, Shields W and Krane DE: Magnitude-dependent variation in peak height balance at heterozygous STR loci. Int J Legal Med. 125:87–94. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Leclair B, Frégeau CJ, Bowen KL and Fourney RM: Systematic analysis of stutter percentages and allele peak height and peak area ratios at heterozygous STR loci for forensic casework and database samples. J Forensic Sci. 49:968–980. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, et al: DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 103:863–875. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Roth AD, Delorenzi M, Tejpar S, Yan P, Klingbiel D, Fiocca R, d'Ario G, Cisar L, Labianca R, Cunningham D, et al: Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst. 104:1635–1646. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Klingbiel D, Saridaki Z, Roth AD, Bosman FT, Delorenzi M and Tejpar S: Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: Results of the PETACC-3 trial. Ann Oncol. 26:126–132. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF and Schilsky RL: American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 27:2091–2096. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, et al: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 29:2011–2019. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 369:1023–1034. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ashktorab H, Smoot DT, Carethers JM, Rahmanian M, Kittles R, Vosganian G, Doura M, Nidhiry E, Naab T, Momen B, et al: High incidence of microsatellite instability in colorectal cancer from African Americans. Clin Cancer Res. 9:1112–1117. 2003.PubMed/NCBI | |
|
Salto-Tellez M, Tan SY, Chiu LL and Koay ESC: Dinucleotide microsatellite repeats are essential for the diagnosis of microsatellite instability in colorectal cancer in Asian patients. World J Gastroenterol. 11:2781–2783. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Asaka S, Arai Y, Nishimura Y, Yamaguchi K, Ishikubo T, Yatsuoka T, Tanaka Y and Akagi K: Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B. Carcinogenesis. 30:494–499. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yamada K, Kanazawa S, Koike J, Sugiyama H, Xu C, Funahashi K, Boland CR, Koi M and Hemmi H: Microsatellite instability at tetranucleotide repeats in sporadic colorectal cancer in Japan. Oncol Rep. 23:551–561. 2010.PubMed/NCBI | |
|
Kim CG, Ahn JB, Jung M, Beom SH, Kim C, Kim JH, Heo SJ, Park HS, Kim JH, Kim NK, et al: Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. Br J Cancer. 115:25–33. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Woerner SM, Benner A, Sutter C, Schiller M, Yuan YP, Keller G, Bork P, Doeberitz M and Gebert JF: Pathogenesis of DNA repair-deficient cancers: A statistical meta-analysis of putative Real Common Target genes. Oncogene. 22:2226–2235. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Yamamoto H, Adachi Y, Taniguchi H, Kunimoto H, Nosho K, Suzuki H and Shinomura Y: Interrelationship between microsatellite instability and microRNA in gastrointestinal cancer. World J Gastroenterol. 18:2745–2755. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Poynter JN, Siegmund KD, Weisenberger DJ, Long TI, Thibodeau SN, Lindor N, Young J, Jenkins MA, Hopper JL, Baron JA, et al Colon Cancer Family Registry Investigators, : Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev. 17:3208–3215. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N and Allegra CJ; National Cancer Institute, : Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol. 25:767–772. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Thibodeau SN, Bren G and Schaid D: Microsatellite instability in cancer of the proximal colon. Science. 260:816–819. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Cho YK, Kim HC, Kim SH, Park JH, Yun HR, Cho YB, Yun SH, Lee WY and Chun HK: Location-related differences in sporadic microsatellite unstable colorectal cancer. Dig Liver Dis. 42:611–615. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Y, Wang G, He J, Ren S, Wu F, Zhang J and Wang F: Gender differences in colorectal cancer survival: A meta-analysis. Int J Cancer. 141:1942–1949. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Gryfe R, Kim H, Hsieh ETK, Aronson MD, Holowaty EJ, Bull SB, Redston M and Gallinger S: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 342:69–77. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 360:1408–1417. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, et al: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 28:466–474. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Yokota T: Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anticancer Agents Med Chem. 12:163–171. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Vaughn CP, Zobell SD, Furtado LV, Baker CL and Samowitz WS: Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer. 50:307–312. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Peeters M, Kafatos G, Taylor A, Gastanaga VM, Oliner KS, Hechmati G, Terwey JH and van Krieken JH: Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. Eur J Cancer. 51:1704–1713. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Guo F, Gong H, Zhao H, Chen J, Zhang Y, Zhang L, Shi X, Zhang A, Jin H, Zhang J, et al: Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients. Sci Rep. 8:60762018. View Article : Google Scholar : PubMed/NCBI | |
|
Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, et al: KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 101:715–721. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K, Williams R and Wiezorek J: Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: Assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol. 31:759–765. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu HC, Thiam TK, Lu YJ, Yeh CY, Tsai WS, You JF, Hung HY, Tsai CN, Hsu A, Chen HC, et al: Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients. Oncotarget. 7:22257–22270. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Li HT, Lu YY, An YX, Wang X and Zhao QC: KRAS, BRAF and PIK3CA mutations in human colorectal cancer: Relationship with metastatic colorectal cancer. Oncol Rep. 25:1691–1697. 2011.PubMed/NCBI | |
|
Hu J, Yan WY, Xie L, Cheng L, Yang M, Li L, Shi J, Liu BR and Qian XP: Coexistence of MSI with KRAS mutation is associated with worse prognosis in colorectal cancer. Medicine (Baltimore). 95:e56492016. View Article : Google Scholar : PubMed/NCBI |
